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Abstract
BACKGROUND: This study was performed to evaluate
the safety and efficacy of paclitaxel with cisplatin as
salvage therapy in patients previously treated with
gemcitabine and cisplatin (G/C) for advanced tran-
sitional cell carcinoma (TCC) of the urothelial tract.
METHODS: Twenty-eight patients with metastatic or
locally advanced TCC who had received prior G/C
chemotherapy were enrolled. All patients received
paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) every
3 weeks for eight cycles or until disease progression.
RESULTS: The median age was 61 years (range, 43–
83 years), and the median Eastern Cooperative Oncol-
ogy Group performance status was 1 (range, 0–2). The
overall response rate was 36% [95% confidence inter-
val (95% CI) = 18–54], with three complete responses
and seven partial responses. The median time to pro-
gression was 6.2 months (95% CI = 3.9–8.5), and the
median overall survival was 10.3 months (95%CI = 6.1–
14.1). The most common Grade 3/4 nonhematologic
and hematologic toxicities were emesis (10 of 28 pa-
tients; 36%) andneutropenia (5 of 110 cycles; 5%).CON-
CLUSIONS: Salvage chemotherapy with paclitaxel and
cisplatin displayed promising results with tolerable
toxicity profiles in patients with metastatic or locally
advanced TCC who had been pretreated with G/C.
Neoplasia (2007) 9, 18–22
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Introduction
Transitional cell carcinoma (TCC) of the urothelium is
characteristically a chemosensitive tumor [1]. Combina-
tion chemotherapy provides both palliation and modest
survival advantage in patients with advanced disease
states. Cisplatin-based combination chemotherapy, such
as M-VAC (methotrexate, vinblastin, doxorubicin, cisplatin),
produced considerable tumor responses of 50% to 70%
and durable improvements in survival in 15% to 20% of pa-
tients [2–5]. A randomized clinical phase III study reported
that M-VAC, when compared to cisplatin alone, had superior
response rates in patients with metastatic urothelial cell carci-
noma [6]. As first-line chemotherapy, the combination of gem-
citabine and cisplatin (G/C) also demonstrated noninferior
antitumor activity but better tolerability and improved safety
profile when compared with M-VAC [7]. As a result, the G/C
combination has become a popular regimen for the first-line
treatment of TCC. However, almost all responding patients
relapse within the first year, with a median survival of 12 to
14 months. In addition, prognosis is very poor in patients
who display progressive disease after receiving combination
cisplatin-based chemotherapy. Therefore, options for salvage
therapy have become important. However, the standard
chemotherapeutic regimen for salvage treatment remains to
be defined. Clinical trials for second-line chemotherapy for
advanced urothelial TCC are warranted [8,9].
Taxane-based chemotherapy is currently the most commonly
used regimen for salvage chemotherapy. Paclitaxel has been
tested as a single agent in both first-line and second-line chemo-
therapies and has shown response rates of between 42% and
56% with 3-week cycle therapy schedules [10–12]. However,
weekly paclitaxel has demonstrated a low response rate of
10% and short time to progression (TTP) when used as salvage
therapy for advanced TCC in small phase II trials [11,13].
Based on these promising results of taxane-based chemo-
therapy and given the absence of standard second-line treat-
ment options, we conducted a phase II study of paclitaxel with
cisplatin as salvage therapy for patients with advanced TCC
who had been previously treated with G/C chemotherapy.
Address all correspondence to: Ho Yeong Lim, MD, PhD, Division of Hematology –Oncology,
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, 50 Ilwon-dong, Gangnam-gu, Seoul 135-710, South Korea.
E-mail: hoylim@smc.samsung.co.kr
Received 11 October 2006; Revised 21 November 2006; Accepted 22 November 2006.
Copyright D 2007 Neoplasia Press, Inc. All rights reserved 1522-8002/07/$25.00
DOI 10.1593/neo.06661
Neoplasia . Vol. 9, No. 1, January 2007, pp. 18 – 22 18
www.neoplasia.com
RESEARCH ARTICLE
Materials and Methods
Patients and Treatment Scheme
From August 2002 to December 2004, patients with
histologically confirmed TCC of the urinary tract (bladder,
ureter, and renal pelvis) were entered into the study. Eligible
patients were required to have had progressive disease
subsequent to a G/C combination chemotherapy, an Eastern
Cooperative Oncology Group (ECOG) performance status
of 0 to 2, and lesions bidimensionally measurable by spiral
computed tomography (CT) scan. Adequate bone marrow,
liver, and renal functions were defined as follows: absolute
neutrophil count z 1500 ml; platelet count z100,000 ml;
bilirubin < 1.5 the upper normal level (UNL); aspartate
aminotransferase and alanine aminotransferase < 2 UNL;
and creatinine V 1 UNL. Patients with other malignancies or
with concurrent uncontrolled medical illness were deemed
ineligible for the study. All patients provided written informed
consent according to our institutional guidelines.
The treatment cycle included intravenous paclitaxel
(175 mg/m2) for 3 hours on day 1; following paclitaxel
infusion, cisplatin (60 mg/m2) was administered intrave-
nously for 1 hour, with adequate hydration. Before paclitaxel
infusion, all patients were prophylactically administered
100 mg of hydrocortisone, 4 mg of chlorpheniramine, and
50 mg of ranitidine 30 minutes before treatment. The treat-
ment was then repeated every 3 weeks and continued until
disease progression or up to eight cycles.
Study Objectives
The objective of the study was to evaluate the safety and
efficacy of paclitaxel plus cisplatin as salvage chemotherapy
in patients with advanced urothelial TCC who had been
previously treated with G/C. The primary end point of this
study was the response rate to chemotherapy. Secondary
end points included TTP, overall survival (OS), and toxicity.
Statistical Analysis
Treatment responses for measurable disease were as-
sessed by spiral CT scans conducted every three cycles of
treatment. Tumor responses were defined as World Health
Organization criteria. OS and response duration were esti-
mated by the Kaplan-Meier product limit method. OS dura-
tion was measured from the day of chemotherapy initiation
up to the day of death. If the patient was lost during the
follow-up period, the status of the patient was confirmed by
telephone with the bereaved family at the time of analysis.
TTP was calculated from the day of treatment initiation up
to the date when progression was noted. Toxicity was mea-
sured according to National Cancer Institute Common Tox-
icity Criteria, version 2.0.
The target response rate of interest was z 25%, whereas
the accrual of patients for the study would be held if the
response probability was V 5%. Nine patients would be
accrued initially in a two-stage study design. If at least one
complete or partial response was noted, an additional eight
patients would be accrued. Nineteen patients were actually
enrolled in the second stage, for a total of 28 patients. The
probability of accepting the study regimen with a response
probability of < 5%was .20, and the probability of rejecting the
study regimen with a response probability of > 25% was .05.
Results
Patients
Nine patients were enrolled from August 2002 to June
2003. Then, an additional nineteen patients were recruited
from July 2003 to December 2004. Baseline patient profiles
and patient characteristics are provided in Table 1. The
median age was 61 years (range, 43–83 years), with a
predominantly male proportion [males, 21 (75%); females,
7 (25%)]. The most common primary site was the bladder
(71%). The most frequently involved site of metastases
was the lung (43%), followed by the bones (29%) and liver
(29%). Twenty-one patients (75%) received G/C chemo-
therapy alone, whereas the remaining seven patients
(25%) receivedG/C chemotherapy in combination with radio-
therapy as first-line treatment. The median number of G/C
cycles was 5 (range, 2–12 cycles). Patients who had intra-
abdominal metastatic lymph nodes or malignant cells on
resected margins after radical surgery received chemo-
therapy with radiotherapy. Patients who received G/C with
radiotherapy (4000 cGy, 16 fractions) underwent six cycles
of G/C chemotherapy.
Patients’ median time to disease progression with G/C
was 6.8 months [95% confidence interval (95% CI) = 1.8–
32.7 months]. Ten patients had progressive diseases within
Table 1. Baseline Characteristics of Patients.
Characteristics n (%)
Total 28 (100)
Age in years [median (range)] 61 (43–83)
Gender
Male 21 (75)
Female 7 (25)
ECOG performance status
0 2 (7)
1 25 (89)
2 1 (4)
Primary site
Bladder 20 (71)
Ureter 7 (25)
Renal pelvis 1 (4)
Initial tumor grade
Unknown 1 (4)
2 2 (7)
3 25 (89)
Metastatic lesions on initiation of paclitaxel and cisplatin
Lung 12 (43)
Bone 8 (29)
Liver 8 (29)
Metastatic lymph nodes without visceral metastasis 7 (25)
Previous treatment
Chemotherapy alone 21 (75)
Chemoradiotherapy 7 (25)
Best response to first-line therapy
Complete response 8 (29)
Partial response 9 (32)
Stable disease 3 (10)
Progressive disease 8 (29)
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6 months of G/C initiation. Seventeen patients (71%) were
responders to prior treatment with G/C. Responders’ me-
dian response duration of G/C was 7.5 months (95% CI =
4.8–10.2 months).
Response and Survival
One of the initial nine patients achieved complete re-
sponse, and one patient achieved partial response. Therefore,
an additional 19 patients were recruited. Finally, 24 (86%) of
28 patients were assessable for response. According to
intention-to-treat analysis, three patients (11%; 95% CI = 0–
23%) obtained a complete response, and seven patients
(25%) obtained a partial response to therapy (95% CI = 9–
41%). An overall response rate (ORR) of 36% (95% CI =
18–54%) was achieved. The ORR excluding four inevaluable
patients was 42% (95% CI = 22–62%). Four patients who
were not evaluable for response composed the inevaluable
response group (Table 2). Three inevaluable patients de-
veloped neutropenic fever after the first cycle did not pro-
ceed with further chemotherapy. One patient suffered from
Grade 3 emesis and gave up further chemotherapy after the
second cycle.
After a median follow-up duration of 16.4 months (range,
2.1–30.7 months), the median OS of all 28 patients was
10.3 months (95% CI = 6.1–14.1 months) and the 1-year
survival rate was 45% (95%CI = 27–63%) (Figure 1). Twelve
patients remained alive at the time of analysis. One of the
survivors stopped chemotherapy due to neutropenic fever
and was followed up for only 2.1 months.
The median TTP for the 24 evaluable patients was
6.2 months (95% CI = 3.9–8.5 months). The median re-
sponse duration was 4.7months (95%CI = 2.8–6.6months).
Among the three complete-response patients, two patients
had lung metastases from bladder cancer and the other
had intraabdominal lymph node metastasis from ureteral
cancer. One patient with lung metastasis died from an acute
left middle cerebral artery infarction but without disease
recurrence at 21.4 months.
Seven (41%) of 17 prior G/C responders showed re-
sponse to paclitaxel and cisplatin compared with 4 (36%) of
11 G/C nonresponders. There was no significant difference in
median OS time between the two groups [G/C responders
(7.5 months, 95% CI = 4.8–10.2 months) versus G/C non-
responders (9.3 months, 95% CI = 4.4–14.3 months)], as
well as in ORR. Among 10 patients with < 6 months of TTP
of G/C (G/C refractory group), one complete response and
two partial responses were achieved after paclitaxel and
cisplatin chemotherapy. The response rate for paclitaxel
and cisplatin of the G/C refractory group and that for the
nonrefractory group did not show statistically significant dif-
ferences. However, the number of patients of each subgroup
was small, and statistical power might be inconclusive.
Toxicity
One hundred ten cycles, with a median number of three
cycles (range, 1–8 cycles), were administered. There was no
treatment-related mortality. In addition, z Grade 3 neutro-
penia occurred in 5% of all cycles and was associated with
infection in 3% of all cycles. Granulocyte colony-stimulating
factor was administered in patients with neutropenic fever.
Three patients could not receive further chemotherapy after
an episode of neutropenic fever because of deteriorated
performance status. Grade 3/4 anemia and thrombocyto-
penia were observed in one cycle (1%) (Table 3).
Ten (36%) of 28 patients suffered from Grade 3/4 emesis,
and one patient refused further chemotherapy after two
treatment cycles. Eight patients (29%) experienced Grade 2
peripheral neuropathy, although seven of eight patients al-
ready had Grade 1 peripheral neuropathy from previous
chemotherapies on study entry (Table 4).
Discussion
Systemic chemotherapy is the treatment modality that has
been most actively evaluated in patients with advanced or
metastatic TCC of the urothelium [14]. Cisplatin is one of
the most effective chemotherapeutic agents for metastatic
urothelial TCC [15]. In the early 1990s, two prospective
Table 2. Response Rates (n = 28).
Best Response n (%)
Complete response 3 (11)
Partial response 7 (25)
Stable disease 6 (21)
Progressive disease 8 (29)
Inevaluable 4 (14)
ORR 10 (36) (95% CI = 18–54%)
Figure 1. Survival curve.
Table 3. Hematologic Toxicities.
Toxicity National Cancer Institute Common Toxicity Criteria
(Per Cycle; n = 110)
Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%)
Neutropenia 10 (9) 8 (7) 3 (3) 2 (2)
Anemia 55 (50) 12 (11) 1 (1) 0 (0)
Thrombocytopenia 16 (15) 3 (3) 1 (1) 0 (0)
Infection with
neutropenia
2 (2) 1 (1)
Infection without
neutropenia
0 (0) 2 (2) 2 (2) 0 (0)
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randomized trials confirmed the superiority of M-VAC
[6,14,16]. Even though M-VAC has been considered the
standard treatment of metastatic TCC, its use can be limited
due to its associated toxicities: myelosuppression, severe
emesis, cardiotoxicity, neurotoxicity, ototoxicity, and nephro-
toxicity [17]. Therefore, therapeutic approaches with newer
agents are necessary to improve response and survival
rates while reducing toxicity profiles [15]. In the past decade,
gemcitabine, paclitaxel, docetaxel, and pemetrexed have
emerged from clinical development for use in the treatment
of TCC [11,18]. A large multinational phase III trial comparing
M-VAC with G/C revealed that G/C had similar antitumor
activities with better tolerability, which was confirmed by
another trial conducted by von der Maase et al. [7,19]. Based
on these reports, G/C appeared to be an appropriate alter-
native for patients with advanced TCC of the urothelium
[7,11,18,19]. Nevertheless, long-term survival of patients with
advanced TCC of the urothelium is still rare. Because most
patients responding to first-line chemotherapy will ultimately
die due to disease progression, the role for salvage treat-
ments will be pivotal in improving survival in these patients.
Several small phase II trials as salvage therapy for ad-
vanced TCC were documented with relatively unsatisfactory
results [11,13,20–23]. A small phase II study for patients with
refractory or relapsed urothelial tumors after methotrexate/
cisplatin–based regimen was reported [20]. The combination
therapy of fluorouracil, folinic acid, and ifosfamide yielded no
objective response [20]. Pagliaro et al. [22] investigated the
antitumor activity of weekly gemcitabine in combination with
cisplatin and ifosfamide in 49 previously treated patients
with advanced TCC. An ORR of 40.8% and an OS duration
of 9.5 months were reported [22]. Taxane-based chemo-
therapy is currently the most commonly used regimen in the
second-line setting [11]. McCaffrey et al. [21] reported that
docetaxel was an active single agent in cisplatin-pretreated
patients with urothelial TCC (n = 30; partial response = 13%;
median survival = 9 months). A small phase II trial of weekly
paclitaxel for salvage therapy demonstrated on ORR of
10% with a median TTP of 2.2 months and a median OS
time of 7.2 months [13]. The combination of paclitaxel and
carboplatin showed modest activity in cisplatin-pretreated
patients with urothelial TCC who had an ORR of 16% (95%
CI = 7–30%) with one complete response (2%), two partial
responses (5%), and four partial responses (9%) that were
unconfirmed. The median progression-free survival was
4 months (95% CI = 3–5 months), and the median survival
was 6 months (95% CI = 5–8 months). The predominant
Grades 3 and 4 toxicities consisted of myelosuppression in
28 patients and peripheral neuropathy in 11 patients [23].
Our study yielded an ORR of 36% with three complete
responses and a median OS of 10.3 months. Several plau-
sible reasons for the high response rate in this study could
be attributed to the substitution of carboplatin for cisplatin
and/or the fact that the majority of patients were documented
responders to previous treatments with G/C (17 partial re-
sponses; 60%). However, there was no significant difference
in survival or ORR between the G/C responders and the
nonresponders. Although reduced nephrotoxicity is an im-
portant advantage of carboplatin, a few randomized phase II
studies comparing regimens using carboplatin versus
cisplatin reported inferior tumor activity with carboplatin-
containing regimens [1,24,25]. A randomized phase II study
performed in 1996 compared M-VECa (methotrexate, vin-
blastin, epirubicin, carboplatin) with M-VEC (methotrexate,
vinblastine, epirubicin, cisplatin). The study demonstrated
an M-VECa response rate of 41%, compared with the 71%
response rate of M-VEC (P = .04) [25]. Bellmunt et al. [24]
reported 39% response rates with M-CAVI (methotrexate,
carboplatin, vinblastine) compared with 52% of M-VAC in a
small randomized trial (P = NS). Prospective randomized
phase III trials are warranted to confirm differences in tumor
activity between carboplatin and cisplatin. A possible reason
for the observed response rates could be that most of the
patients (96%) had an ECOG performance status of 0 or 1,
whereas other similar phase II studies included less patients
with good performance (77% with a ECOG performance
status of 0 or 1) [23]. In addition, the inclusion of patients
with only lymph node metastases without visceral metas-
tasis who received chemoradiotherapy could explain the high
response rates in our study groups.
The current study was a small clinical phase II study for
patients with advanced TCC who were pretreated with G/C
in a single institute. However, paclitaxel with cisplatin appears
to be a relatively promising regimen for patients with uro-
thelial TCC who were pretreated with G/C. Therefore, sal-
vage chemotherapy with paclitaxel and cisplatin may be
considered in these patients, and further clinical trials are
definitely warranted.
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